Also known as: Buprenorphine hydrochloride
Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the μ (mu) and κ (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the μ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Buprenorphine is the active ingredient of these drugs:
Austria
United States
United Kingdom
United Kingdom
Austria Germany
United Kingdom
Germany
Australia
Germany
Germany
United States
Austria
Austria
Spain
United Kingdom
Canada Germany Ireland Netherlands Tunisia
Australia Austria Ireland Lithuania Spain
United Kingdom
Ireland United Kingdom
Spain
Spain
United Kingdom
United Kingdom
Brazil
Australia Austria Germany Hong Kong Lithuania
France
United Kingdom
United Kingdom
Canada
United Kingdom
Ireland United Kingdom
United Kingdom
Brazil
United Kingdom
Austria Ireland Lithuania United Kingdom
Singapore
Australia Canada United States
Australia Austria France Germany Ireland
Austria France Germany Hong Kong Ireland
Austria Brazil Germany Ireland Netherlands
Buprenorphine is also found within below combination drugs:
BUNALICT , BUNAVAIL , BUPENSAN DUO , SUBOXONE , ZUBSOLV
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):